Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport
  Aeronautics
  Intermodality
  Rail
  Road
  Water-borne - incl. marine, inland
  Other

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


This page was published on 14/04/2005
Published: 14/04/2005

   Transport

Last Update: 14-04-2005  
Related category(ies):
Health & life sciences  |  Research policy  |  Environment  |  Pure sciences  |  Transport

 

Add to PDF "basket"

European project gives booster shot to antibiotics research

Faced with increasing levels of antibiotic resistance which put human health at risk, several EU-backed research teams, such as the ActinoGEN integrated project, are on the hunt for new antibiotics. But they face many challenges, including overcoming the misuse of current antibiotics in both human and animal health, as well as flagging investment in new antibiotics by the world's drug makers.

EU project set to tackle the antibiotic resistance problem facing the medical world. © PhotoDisc
EU project set to tackle the antibiotic resistance problem facing the medical world.
© PhotoDisc
Multiple drug resistant bacteria are a major and rapidly increasing threat to human health, placing a heavy burden on already stretched medical budgets. Two courses of action are necessary. Effort is needed to tackle the root causes of antibiotic resistance by reducing their use in animal husbandry and limiting current prescription practices for non-lethal human diseases. More research is also necessary to develop new antibiotics to fill the gap in the meantime.

ActinoGEN – which stands for ‘Integrating genomics-based applications to exploit actinomycetes as a resource for new antibiotics' – is actively pursuing the second path. With €9 million in European Union funding, the project will combine new genomic technologies with chemical analysis to take advantage of microbial genetic resources for new antibiotics. The team also plans to develop what it calls “generic superhosts” in order to produce these new antibiotics in sufficiently high yields.

To herald the start of this new five-year integrated research project, funded under the Union's Sixth Framework Programme (FP6) research in the life sciences, scientists from across Europe are gathering today at Swansea University (UK). According to the group, they are mapping out how the joint research can fully exploit nature's most prolific antibiotic factories, the actinomycetes, to help alleviate the current crisis in treatment of multiple drug-resistant diseases. Such antibiotics could provide treatments of last resort for life-threatening diseases including tuberculosis and nosocomial infections like MRSA.

Major impact on healthcare
The project is coordinated by Dr Paul Dyson of the Molecular Biology Research department at Swansea and is made up of 14 EU universities, together with a South Korean partner and three European small- and medium-sized companies. He commented that this pan-European research effort will help scientists better understand the physiology and regulation of antibiotic biosynthesis in actinomycetes.

“This, in turn, can help us develop strategies to ‘turn-on' production of new antibiotics that can be used to combat life-threatening infections like MRSA,” he said, adding that “it will put the European biotechnology sector at the forefront of developing much-needed new antibiotics to combat multi-drug resistant disease.”       

Of particular concern are antibiotic-resistant nosocomial infections. The socio-economic costs of these hospital-acquired infections are enormous, the team stressed at the meeting. For example, the UK National Health Service estimates that these infections cost €1.5 billion in extra patient care and are responsible for 5 000 deaths each year.

“There is a potential for [our] new antibiotics to make a major impact on healthcare in the EU, both at the level of the individual patient and also on healthcare budgets by reducing treatment times in hospitals,” Dr Dyson predicts.

EU project ActinoGEN

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

Dr Paul Dyson

ActinoGEN news (on University of Wales Swansea website)

Life sciences research in FP6 (on Europa)

Antibiotic resistance – a growing threat (EU Research in Action series)


Contacts
Research Contacts page
  Top   Research Information Center